LD5097

LD5097 is a highly effective and selective PROTAC degrader targeting RIPK1. LD5097 can rapidly and efficiently downregulate RIPK1 and significantly enhance TNFα-mediated apoptosis in Jurkat cells. LD5097 significantly increases the levels of cleaved caspase-3/7 and PARP. LD5097 can be used for the study of acute T-lymphoblastic leukemia[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Caspase; PARP; PROTACs; RIP kinase

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PROTAC

Field of Research

Cancer

Smiles

O=C(N1CCC2=C1C=CC(C3=CN(C4=NC=NC(N)=C34)C5CCN(CC5)C(C6=CC=C(C=C6)C#CC7=CN=C(C=C7)N8CCN(CC8)C(C[C@@H](C9=CC=C(C=C9)C%10=C(N=CS%10)C)NC([C@@H]%11C[C@H](CN%11C([C@@H](NC(C%12(CC%12)F)=O)C(C)(C)C)=O)O)=O)=O)=O)=C2)CC%13=CC=CC(OC(F)(F)F)=C%13

Molecular Formula

C74H75F4N13O8S

Molecular Weight

1382.53

References & Citations

[1]Lu D, et al. Design, Optimization, and Development of RIPK1 Degraders with Improved Pharmacokinetic and Pharmacodynamic Properties. J Med Chem. 2025 Nov 13;68 (21) :22246-22263.